Jason C Pradarelli1, Oliver A Varban2, Justin B Dimick2. 1. Center for Healthcare Outcomes and Policy, University of Michigan, Ann Arbor, Michigan; University of Michigan Medical School, Ann Arbor, Michigan. Electronic address: jcprad@med.umich.edu. 2. Center for Healthcare Outcomes and Policy, University of Michigan, Ann Arbor, Michigan; Department of Surgery, University of Michigan, Ann Arbor, Michigan; Michigan Bariatric Surgery Collaborative, University of Michigan, Ann Arbor, Michigan.
Abstract
BACKGROUND: Postoperative gastroesophageal reflux is one of the most important long-term complications of sleeve gastrectomy, the most common bariatric procedure. OBJECTIVE: To assess variation in hospital performance with laparoscopic sleeve gastrectomy using rates of acid-reducing medication use at postoperative 1 year. SETTING: Clinical registry of bariatric surgical patients at academic and community hospitals in Michigan. METHODS: We studied 2923 patients who underwent laparoscopic sleeve gastrectomy across 39 hospitals in the Michigan Bariatric Surgery Collaborative, 2007 to 2014. We compared risk- and reliability-adjusted rates of new-onset reflux-defined by new use of acid-reducing medication-across hospitals and in relation to surgical quality indicators (hospital procedure volume and 30-day complications). RESULTS: Overall, 20% of patients were newly taking acid-reducing medication at postoperative 1 year. Hospital rates of new medication use varied 3-fold, ranging from 10% (95% CI 7-15%) to 31% (95% CI 23-40%) of patients. Of the 2 hospitals with significantly lower rates of new medication use, 1 was high volume and 1 was medium volume. The 1 hospital with significantly higher rates was medium volume. Rates of acid-reducing medication use did not correlate with hospital volume or perioperative complications. CONCLUSION: Across Michigan hospitals, rates of new acid-reducing medication use at 1 year after laparoscopic sleeve gastrectomy varied widely and did not correlate with traditional quality indicators. Future research could explore differences in surgical technique to better understand the factors underlying variation in long-term outcomes after sleeve gastrectomy.
BACKGROUND:Postoperative gastroesophageal reflux is one of the most important long-term complications of sleeve gastrectomy, the most common bariatric procedure. OBJECTIVE: To assess variation in hospital performance with laparoscopic sleeve gastrectomy using rates of acid-reducing medication use at postoperative 1 year. SETTING: Clinical registry of bariatric surgical patients at academic and community hospitals in Michigan. METHODS: We studied 2923 patients who underwent laparoscopic sleeve gastrectomy across 39 hospitals in the Michigan Bariatric Surgery Collaborative, 2007 to 2014. We compared risk- and reliability-adjusted rates of new-onset reflux-defined by new use of acid-reducing medication-across hospitals and in relation to surgical quality indicators (hospital procedure volume and 30-day complications). RESULTS: Overall, 20% of patients were newly taking acid-reducing medication at postoperative 1 year. Hospital rates of new medication use varied 3-fold, ranging from 10% (95% CI 7-15%) to 31% (95% CI 23-40%) of patients. Of the 2 hospitals with significantly lower rates of new medication use, 1 was high volume and 1 was medium volume. The 1 hospital with significantly higher rates was medium volume. Rates of acid-reducing medication use did not correlate with hospital volume or perioperative complications. CONCLUSION: Across Michigan hospitals, rates of new acid-reducing medication use at 1 year after laparoscopic sleeve gastrectomy varied widely and did not correlate with traditional quality indicators. Future research could explore differences in surgical technique to better understand the factors underlying variation in long-term outcomes after sleeve gastrectomy.
Authors: John D Birkmeyer; Andrea E Siewers; Emily V A Finlayson; Therese A Stukel; F Lee Lucas; Ida Batista; H Gilbert Welch; David E Wennberg Journal: N Engl J Med Date: 2002-04-11 Impact factor: 91.245
Authors: Brahmajee K Nallamothu; Hitinder S Gurm; Henry H Ting; Philip P Goodney; Mary A M Rogers; Jeptha P Curtis; Justin B Dimick; Eric R Bates; Harlan M Krumholz; John D Birkmeyer Journal: JAMA Date: 2011-09-28 Impact factor: 56.272
Authors: Mehraneh D Jafari; Fariba Jafari; Monica T Young; Brian R Smith; Michael J Phalen; Ninh T Nguyen Journal: Surg Endosc Date: 2013-08-13 Impact factor: 4.584
Authors: Oliver A Varban; Abdelkader A Hawasli; Arthur M Carlin; Jeffrey A Genaw; Wayne English; Justin B Dimick; Michael H Wood; John D Birkmeyer; Nancy J O Birkmeyer; Jonathan F Finks Journal: Surg Obes Relat Dis Date: 2014-05-10 Impact factor: 4.734
Authors: Mario Musella; Antonio Susa; Emilio Manno; Maurizio De Luca; Francesco Greco; Marco Raffaelli; Stefano Cristiano; Marco Milone; Paolo Bianco; Antonio Vilardi; Ivana Damiano; Gianni Segato; Laura Pedretti; Piero Giustacchini; Domenico Fico; Gastone Veroux; Luigi Piazza Journal: Obes Surg Date: 2017-11 Impact factor: 4.129